Curis Inc
CRIS Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 23, 2026
$0.39
KIRA · Stoqly’s AI analyst, in plain words
- Curis Inc had $9.4M of revenue in fiscal 2025, down 13.4% on the year before. Over five years, revenue changed −2.7% a year on average.
- Its operating margin was −60.5%, up 347.8 pts: of every 100 in sales, about −60 is left after running the business.
- Curis Inc lost $7.6M in fiscal 2025.
- Curis Inc has $5.1M more cash than debt.
Market cap
$0.8M
P/E
0.0x
Revenue
$9.4M
Net income
−$7.6M
Free cash flow
—
Operating margin
−60.5%
Curis Inc in 30 seconds · fiscal 2025
Are sales growing?
−13.4%
No. Sales fell 13.4% last year.
Does it make a profit?
−80.3%
No. It lost money last year.
How healthy are the accounts?
3 / 8
Weak. It passes 3 of 8 health tests.
How is the share priced?
0.0x
One share costs 0.0 times its yearly profit per share.
What Curis Inc does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 24, 2026
- Legal name
- CURIS INC
- CIK
- 0001108205
Curis Inc · CRIS
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $10.6M | $10.2M | $10.0M | $10.9M | $9.4M |
| Revenue growth | −1.7% | −4.6% | −1.4% | 8.8% | −13.4% |
| Operating margin | −395.0% | −521.7% | −482.2% | −408.3% | −60.5% |
| Net income | −$45.4M | −$56.7M | −$47.4M | −$43.4M | −$7.6M |
| Net margin | −426.7% | −557.7% | −473.0% | −397.8% | −80.3% |
| Diluted EPS | $0.50 | −$12.14 | −$8.96 | −$6.88 | −$0.58 |
| Cash | |||||
| Cash from operations | −$37.6M | −$54.3M | −$38.4M | −$39.6M | −$27.2M |
| Capital expenditure | $0.0M | $0.4M | $0.0M | — | — |
| Free cash flow | −$37.6M | −$54.8M | −$38.4M | — | — |
| FCF margin | −353.3% | −538.8% | −383.5% | — | — |
| Share count change | 88.1% | −94.9% | 13.4% | 19.1% | 108.7% |
| Debt and strength | |||||
| Cash and short-term investments | $116M | $85.6M | $56.3M | $20.0M | $5.1M |
| Debt incl. finance leases | $0.0M | — | $8.5M | $7.6M | $0.0M |
| Shareholders' equity | $90.7M | $46.6M | $19.7M | −$6.0M | $5.5M |
| Current ratio | 9.1x | 9.2x | 2.8x | 1.4x | 0.5x |
| Returns and quality | |||||
| Return on capital | — | — | — | — | −1,125.5% |
| Return on equity | −41.0% | −82.6% | −143.2% | −634.7% | — |
| Return on tangible equity | −55.6% | −150.8% | −443.6% | — | — |
| Piotroski F-score | 3 | 4 | 2 | 2 | 3 |
| Altman Z'' | −17.9 | −32.0 | −51.0 | −104.2 | −207.5 |
Insiders bought, 12 months
$0.0M
1 insider
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Curis Inc · CRIS
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.39 a share, the company is worth $0.8M: 0.0 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001108205). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.